Compounds > lutetium
Page last updated: 2024-08-22

lutetium and Angiogenesis, Pathologic

lutetium has been researched along with Angiogenesis, Pathologic in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Elgström, E; Eriksson, SE; Nilsson, R; Ohlsson, T; Örbom, A; Strand, SE; Tennvall, J1
Díaz-Nieto, L; Ferro-Flores, G; Gómez-Oliván, L; Jiménez-Mancilla, N; Luna-Gutiérrez, M; Morales-Avila, E; Ocampo-García, B; Pedraza-López, M; Santos-Cuevas, C; Vilchis-Juárez, A1
Chung, JK; Jeong, JM; Jeong, SY; Ju, CH; Kim, YJ; Lee, BC; Lee, DS; Lee, MC; Lee, YS1
Backer, JM; Backer, MV; Blankenberg, FG; Goris, MG; Hamby, CV; Levashova, Z1

Other Studies

4 other study(ies) available for lutetium and Angiogenesis, Pathologic

ArticleYear
The intratumoral distribution of radiolabeled 177Lu-BR96 monoclonal antibodies changes in relation to tumor histology over time in a syngeneic rat colon carcinoma model.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013, Volume: 54, Issue:8

    Topics: Animals; Antibodies, Monoclonal; Colonic Neoplasms; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Humans; Immunoconjugates; Isotope Labeling; Lewis Blood Group Antigens; Lutetium; Male; Neovascularization, Pathologic; Radiation Dosage; Radioisotopes; Rats; Time Factors

2013
Molecular targeting radiotherapy with cyclo-RGDFK(C) peptides conjugated to 177Lu-labeled gold nanoparticles in tumor-bearing mice.
    Journal of biomedical nanotechnology, 2014, Volume: 10, Issue:3

    Topics: Animals; Antineoplastic Agents; Cells, Cultured; Chemoradiotherapy; Gold; Lutetium; Male; Metal Nanoparticles; Mice; Mice, Nude; Molecular Targeted Therapy; Nanoconjugates; Neoplasms; Neovascularization, Pathologic; Peptides, Cyclic; Radioisotopes; Rats; Xenograft Model Antitumor Assays

2014
Development of a ¹⁷⁷Lu-labeled RGD derivative for targeting angiogenesis.
    Cancer biotherapy & radiopharmaceuticals, 2010, Volume: 25, Issue:6

    Topics: Animal Structures; Animals; Chelating Agents; Chromatography, High Pressure Liquid; Colonic Neoplasms; Drug Delivery Systems; Drug Stability; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Kidney; Lutetium; Male; Mice; Mice, Inbred BALB C; Molecular Structure; Neovascularization, Pathologic; Oligopeptides; Radioisotopes; Radiopharmaceuticals; Tissue Distribution

2010
Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2011, Volume: 52, Issue:10

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Apoptosis; Bevacizumab; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Endothelial Cells; Female; Humans; Indoles; Lutetium; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, SCID; Neovascularization, Pathologic; Pyrroles; Radioisotopes; Radiopharmaceuticals; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A

2011